Abstract
The use of a cold-air scalp-cooling system to prevent alopecia following administration of anthracycline chemotherapy is described. The unit used is mounted on a four-wheeled trolley and is highly mobile. Twenty-four patients with advanced breast cancer received epirubicin chemotherapy, 14 at a dose of 50 mg/m2, and 10 at a dose of 100 mg/m2. All 10 patients receiving 100 mg/m2 developed total alopecia; by contrast, only two out of 14 receiving 50 mg/m2 had alopecia, while the remaining 12 retained their hair. Patients not receiving scalp-cooling inevitably developed total alopecia after three pulses of epirubicin.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
